Latest News

(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s non-prostate cancer session included a presentation by Dr. Thomas Powles discussing the IMvigor011 trial concept and design, a phase 3 trial assessing atezolizumab versus placebo as adjuvant therapy in patients with high-risk muscle-invasive bladder cancer (MIBC) who are ctDNA positive after a radical cystectomy.

(UroToday.com) As a portion of the European Society for Medical Oncology (ESMO) Annual Congress, an Educational Session focused on personalized care in genitourinary cancers was held. In this context, Dr. Christian Kollmannsberger presented the role of microRNA in testis cancer.

(UroToday.com) As a portion of the European Society for Medical Oncology (ESMO) Annual Congress, an Educational Session focused on the management of patients with node-positive locally advanced prostate cancer was held. In this context, Dr. Silke Gillessen discussed the role of systemic therapy and novel, emerging treatment approaches.

(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s prostate cancer session included a presentation by Dr. Stephen Freedland discussing treatment patterns and overall survival among men with metastatic castration-sensitive prostate cancer (mCSPC). Indeed, androgen deprivation therapy (ADT) remains the backbone of therapy for mCSPC. While earlier studies (pre-2012) adding first-generation nonsteroidal antiandrogens to […]

(UroToday.com) In this presentation, Dr. Srikala Sridhar discussed results from the Phase 2 NORSE study of erdafitinib or erdafitinib plus cetrelimab in patients with metastatic or locally advanced urothelial carcinoma (UC) and fibroblast growth factor receptor (FGFR) alterations. This study addresses a significant unmet clinical need for better first-line therapy options for patients with metastatic UC […]

(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s prostate cancer session included a presentation by Dr. Byung Ha Chung discussing the efficacy and safety of apalutamide use in Asian patients with metastatic castration-sensitive prostate cancer (mCSPC). In TITAN study, the addition of apalutamide to androgen deprivation therapy (ADT) significantly improved radiographic progression-free survival […]

(UroToday.com) In this presentation, Dr. Thomas Powles presented results from the Phase 2 NORSE study of erdafitinib or erdafitinib plus cetrelimab in patients with metastatic or locally advanced urothelial carcinoma (UC) and fibroblast growth factor receptor (FGFR) alterations. These preliminary results discussed by Dr. Thomas Powles focused on overall response rate (ORR) and safety data.

(UroToday.com) In the on-demand poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Guillermo De Velasco discussed the CABOPRE trial, a single-arm prospective multicentre phase II trial to assess the efficacy and safety of neoadjuvant cabozantinib in patients with clear cell metastatic renal cell carcinoma (mRCC) and potential candidates to cytoreductive […]

(UroToday.com) As a portion of the European Society for Medical Oncology (ESMO) Annual Congress, an Educational Session focused on personalized care in genitourinary cancers was held. In this context, Dr. Matthew Galsky presented the role of tissue and blood-based biomarkers for urothelial cancer.

(UroToday.com) In the on-demand poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Christopher Darr presented results of the phase II NIVOSWITCH trial assessing whether a 1st line switch-maintenance approach (CPI after TKI) improved outcome in metastatic clear cell renal cell carcinoma (mRCC). Each of these treatment approaches (CP and TKI) […]